Dr. Lal Pathlabs reports strong FY25 results, dividend increase

Dr. Lal Pathlabs (BSE:LALPATHLAB) reported strong audited financial results for the quarter and fiscal year ended March 31, 2025, marking a year of growth and strategic development. Consolidated revenue for FY25 reached INR2,461 crore, a 10.5% increase year-over-year, while EBITDA rose by 14.2% to INR696 crore. Profit After Tax (PAT) saw a significant surge of 35.9%, landing at INR492 crore. The company reported a 10.5% increase in revenue for Q4 FY25 reaching INR603 crore, EBITDA was INR169 crore, an increase of 16.9% and PAT was INR156 crore, an increase of 81.4%. Volume-led growth was attributed to deeper market penetration and strategic expansion, including the West region, which contributed 14% of Q4 FY25 revenue.